Filing Details
- Accession Number:
- 0001209191-15-064024
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-08-05 16:14:28
- Reporting Period:
- 2015-08-03
- Filing Date:
- 2015-08-05
- Accepted Time:
- 2015-08-05 16:14:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1215126 | G Margaret Mcglynn | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-08-03 | 12,500 | $57.27 | 13,588 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-08-03 | 3,200 | $136.49 | 10,388 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-08-03 | 6,500 | $137.26 | 3,888 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-08-03 | 2,700 | $138.22 | 1,188 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-08-03 | 100 | $138.98 | 1,088 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Acquisiton | 2015-08-03 | 12,500 | $0.00 | 12,500 | $57.27 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
12,500 | 2021-05-11 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $136.49 (range $135.89 to $136.88).
- Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $137.26 (range $136.91 to $137.90).
- Open market sales reported on this line occurred at a weighted average price of $138.22 (range $137.94 to $138.92).
- Fully vested.